Cencora, Inc. (COR)
| Market Cap | 63.13B -2.3% |
| Revenue (ttm) | 332.77B +5.1% |
| Net Income | 2.62B +38.3% |
| EPS | 13.46 +39.1% |
| Shares Out | 190.83M |
| PE Ratio | 24.58 |
| Forward PE | 17.12 |
| Dividend | $2.40 (0.73%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 1,347,723 |
| Open | 336.79 |
| Previous Close | 330.53 |
| Day's Range | 330.20 - 340.19 |
| 52-Week Range | 244.82 - 377.54 |
| Beta | 0.57 |
| Analysts | Buy |
| Price Target | 371.67 (+12.34%) |
| Earnings Date | Nov 4, 2026 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for COR stock is "Buy." The 12-month stock price target is $371.67, which is an increase of 12.34% from the latest price.
News
Cencora price target raised to $377 from $346 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cencora (COR) to $377 from $346 and keeps an Overweight rating on the shares.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ)
BALA CYNWYD, Pa., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Cencora price target raised to $345 from $330 at BofA
BofA raised the firm’s price target on Cencora (COR) to $345 from $330 and keeps a Neutral rating on the shares after the company announced an agreement to acquire American…
Cencora sees FY26 adjusted EPS to be at least $17.90
Cencora (COR) last night updated its FY26 financial guidance to reflect the strength of the U.S. Healthcare Solutions reportable segment. Cencora now expects adjusted diluted earnings per share to be…
Cencora price target raised to $375 from $373 at Baird
Baird raised the firm’s price target on Cencora (COR) to $375 from $373 and keeps an Outperform rating on the shares. The firm updated its model following the sizable MSO…
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)
BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Cencora to acquire American Oncology Network in $2.4B transaction
Cencora (COR) has signed a definitive agreement to acquire American Oncology Network (AONC), a physician-led network of more than 350 oncology providers across 21 states. AON has built a physician-led...
Cencora to acquire American Oncology Network in $2.4 billion deal
Drug distributor Cencora said on Wednesday it would acquire American Oncology Network in a deal valuing the cancer care provider at up to $2.4 billion, deepening its reach in community oncology acro...
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), ...
Cencora price target raised to $380 from $340 at Argus
Argus analyst David Toung raised the firm’s price target on Cencora (COR) to $380 from $340 and keeps a Buy rating on the shares. The firm sees sustainable earnings growth…
Cencora price target lowered to $400 from $430 at UBS
UBS lowered the firm’s price target on Cencora (COR) to $400 from $430 and keeps a Buy rating on the shares.
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the op...
Cencora appoints Robert Sanchez to board of directors
Cencora (COR) announced that its Board of Directors has elected Robert Sanchez as a new independent director, effective October 1. Sanchez is the Executive Chair of Ryder System, Inc., where…
Cencora Elects Robert E. Sanchez to Its Board of Directors
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sa...
Cencora Transcript: 2026 Global Healthcare Conference
Leadership highlighted a smooth CFO transition, a focus on specialty pharma and MSO growth, and disciplined capital deployment. MSOs are expected to drive profitability by 2027, with stable customer relationships and no major strategic shifts planned.
Cencora sees ‘wraparound’ impact in 2027 from Walgreens
Says Walgreens “has been an important strategic partner for us over a long period of time. We have an excellent relationship with their new team, and we will continue to…
Cencora Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynamics are being managed proactively, with capital allocation priorities unchanged.
Cencora Transcript: Wells Fargo 21st Annual Healthcare Conference
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and MSO expansion offer future opportunities. Independent pharmacies remain resilient.
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solution...
Cencora initiated with a Sector Perform at RBC Capital
RBC Capital initiated coverage of Cencora (COR) with a Sector Perform rating and $330 price target The company’s “pharma-aligned and integrated platform” will benefit from growth in specialty pharma, ...
Cencora still sees FY26 adjusted EPS $17.75-$17.95, consensus $17.86
12:44 EDT Cencora (COR) still sees FY26 adjusted EPS $17.75-$17.95, consensus $17.86
Cencora says some Walgreens volume moving outside company
Says prime vendor pact is unchanged. Says development fully contemplated in guidance.
Cencora says some Walgreens volume moving away, affirms outlook
Cencora (COR) disclosed that beginning July 1, certain Walgreens volume that was being serviced by Cencora separate from the prime vendor agreement began moving outside the company. “The prime vendor…
Leerink sees Cencora’s loss of part of Walgreens business as ‘fairly limited’
Leerink says that losing any business from the largest customer such as Cencora (COR) did with Walgreens is never good. With that said, the firm believes the magnitude incorporated in…
Cencora price target raised to $346 from $342 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cencora (COR) to $346 from $342 and keeps an Overweight rating on the shares.